Anixa Biosciences Inc (ANIX) 10-Q Quarterly Report March 2019

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jan. 31, 2019	Mar. 08, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Anixa Biosciences Inc
Document Type	10-Q
Current Fiscal Year End Date	--10-31
Entity Common Stock, Shares Outstanding		19,628,129
Amendment Flag	false
Entity Central Index Key	0000715446
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jan. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/715446/000151316219000075/form10q.htm

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Earnings

Expense

Cash Flow

Income

Product

Other

Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Other - Other Highlight
The net loss attributable to noncontrolling interest, representing Wistars 5% ownership interest in Certaintys net loss, increased by approximately $58,000 to approximately $85,000 in the three months ended January 31, 2019, from approximately $27,000 in the three months ended January 31, 2018, as Certaintys net loss increased.

Financial - Earnings Highlight
As such, the earnings process was complete and revenue has been recognized upon the execution of the agreement, when collectability was reasonably assured, and when all other revenue recognition criteria were met.
Financial - Expense Highlight
The increase in Certaintys net loss was primarily due to increases in employee stock option compensation expense and employee stock award compensation expense.
Financial - Cash Flow Highlight
We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all.
Other - Other Highlight
As a result, our cash, cash equivalents, and short-term investments at January 31, 2019 increased approximately $847,000 to approximately $5,903,000 from approximately $5,056,000 at the end of fiscal year 2018.
Financial - Cash Flow
The impairment in carrying amount...Read more
Financial - Expense
20 General and Administrative Expenses...Read more
Financial - Expense
The increase in research and...Read more
Financial - Income
Interest income increased by approximately...Read more
Financial - Expense
The increase in general and...Read more
Revenue - Product
Additionally, the sale of equity...Read more
Other - Other
Cash provided by investing activities...Read more
Revenue - Product
Cash provided by financing activities...Read more
Revenue - Product
22 We believe that, of...Read more
Financial - Shares
If current cash on hand,...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001513162-19-000075
Submitted to the SEC: Wed Mar 13 2019 12:29:29 PM EST
Accepted by the SEC: Wed Mar 13 2019
Period: Thursday, January 31, 2019
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-19-000075.htm

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly report for the period ending Thursday, January 31, 2019

SEC Filings

ANIX Valuations

ANIX Annual Reports

ANIX Quarterly Reports

ANIX Corporate News